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ABSTRACT: Background. Management of head and neck carcinoma
from unknown primary (HNCUP) remains controversial, with neck dissec-
tion and radiotherapy (RT) or definitive RT both commonly used. The pur-
pose of this study was to characterize HNCUP and retrospectively
compare outcomes for patients treated with neck dissection1 RT versus
definitive RT.
Methods. From 1994 to 2009, 41 patients with HNCUP underwent either
neck dissection1 RT (n5 22) or definitive RT6 concurrent chemother-
apy (n5 19) at our institution. Treatment outcomes were compared
using Kaplan–Meier methods and log-rank test.
Results. There were no differences between patients treated with neck
dissection1 RT and definitive RT in overall survival (OS), progression-
free survival (PFS), locoregional relapse-free survival (LRFS), freedom
from locoregional failure (FFLRG), or freedom from distant failure (FFDF).
Among 17 patients who underwent neck dissection1 RT for whom
human papillomavirus (HPV) status could be determined, HPV(1)
patients trended toward improved OS (p5 .06) and PFS (p5 .15).
Conclusion. Neck dissection and postoperative RT resulted in similar out-
comes as definitive RT. The prognostic implications of HPV(1) nodes in
HNCUP are similar to those in oropharyngeal primary cancers. VC 2013
Wiley Periodicals, Inc. Head Neck 36: 1589–1595, 2014
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INTRODUCTION
The management of head and neck carcinoma from
unknown primary (HNCUP) remains a therapeutic
dilemma. Treatment options consist of surgery alone,
radiotherapy (RT) alone, or combined-modality treat-
ment.1,2 The primary objectives are to treat mucosal
surfaces at highest risk of harboring the primary tumor,
eliminate the risk of nodal recurrence, and control poten-
tial metastatic disease, with most published series advo-
cating neck dissection followed with RT or, in recent
years, chemoradiotherapy.3–5
Although single modality therapy with either neck dissec-
tion or RT alone provide similar locoregional control in
patients with HNCUP with N1 and selected N2a nodal
classification without extracapsular extension (ECE), more
advanced stage disease managed with up-front neck
dissection requires additional adjuvant RT or chemoradio-
therapy.1,6,7 The use of multiple treatment modalities, how-
ever, may increase the toxicity and morbidity of therapy
compared to single modality therapy.8,9 Few retrospective
studies have been published investigating the use of defini-
tive RT, either with or without concomitant chemotherapy,
in the treatment of advanced neck stage HNCUP.3,10 We
examined our institutional experience to assess whether neck
dissection has an additional benefit to RT in these patients,
and assessed human papillomavirus (HPV) in available nodal
tissue to assess whether the presence of HPV infection in
HNCUP is associated with favorable outcomes analogous to
those observed in HPV-associated oropharyngeal cancer.11
MATERIALS AND METHODS
The medical records of all patients with head and neck
cancer treated in the departments of otolaryngology–head
and neck surgery and radiation oncology at the University
of Michigan between January 1994 and January 2009
were queried under an Institutional Review Board
approved protocol. Patients with biopsy-confirmed squa-
mous cell carcinoma (SCC) limited to the cervical lymph
nodes without an identifiable primary tumor who received
RT at the University of Michigan were eligible for the
present analysis. Clinical neck classification was assigned
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retrospectively according to the American Joint Commit-
tee on Cancer Staging Manual 7th edition.
Diagnostic workup
SCC in the cervical lymph nodes was biopsy proven in
all patients by either fine-needle aspiration or excisional
biopsy. Pretreatment initial diagnostic workup included
physical examination, chest X-ray, direct endoscopic
examination under anesthesia, panendoscopy with random
biopsies, and CT and/or MRI of the head and neck. In
recent years, positron emission tomography (PET)/CT and
tonsillectomy were routinely performed in an effort to
identify the primary tumor.
Treatment
After diagnosis and staging, patients were treated with
either a combination of neck dissection and adjuvant RT
or definitive RT. The choice of treatment modality was
according to physician preference, as no uniform policy
existed. All patients in the neck dissection1RT group
underwent either radical or modified radical neck
dissection.
All patients received RT using either 3-dimensional
conformal radiation therapy or intensity-modulated radia-
tion therapy (IMRT); IMRT was routinely used after
2002. Irrespective of RT technique, targets and organs at
risk were outlined on the treatment planning CT. For
definitive RT, the gross target volume was defined as all
known neck disease based on clinical examination and
imaging. Clinical target volume-1 (CTV-1) was defined
as gross target volume with typical margins of 0.5 to 1
cm. CTV-2 included potential primary mucosal sites, typ-
ically the bilateral base of the tongue and ipsilateral ton-
sillar fossa, larynx, hypopharynx, and nasopharynx, with
the oral cavity and the contralateral larynx typically
excluded. Primary mucosal site targets, however, were
individualized according to risk factor profile; in patients
without a history of smoking, for example, the hypophar-
ynx and larynx were omitted from the targets. CTV-2
also included lymph node levels at risk of microscopic
disease, typically levels I to V in the ipsilateral neck and
II to IV in the contralateral neck, with ipsilateral level IB
included if level II neck node involvement was >N1. The
planning target volume, aimed to accommodate setup
uncertainties, was typically obtained by adding a 5-mm
volumetric expansion to the CTVs. This expansion was
reduced in recent years to 3 mm, as daily imaging was
introduced to assess and correct setup errors. Prescription
doses were typically 70 Gy to CTV-1 and 56 to 59 Gy to
CTV-2, all delivered simultaneously over 35 fractions in
the IMRT cases, whereas in the 3D cases, all targets
received 50 Gy at 2 Gy/fractions and CTV-1 was subse-
quently boosted with an additional 20 Gy to a total of
70 Gy.
For adjuvant cases, CTV-1 encompassed the neck lev-
els, which contained grossly and pathologically involved
lymph nodes and adjacent levels considered to be at high-
est risk for microscopic disease. Potential primary muco-
sal sites and lymph nodes levels at lower risk were
included in CTV-2. Prescription doses were typically 60
Gy to CTV-1 and 54 Gy to CTV-2, all given in 30 frac-
tions over 6 weeks. Sites of ECE received 66 Gy, either
by an electron beam boost of 3 additional fractions or, in
more recent years, as boost integrated into the IMRT
plan. Organs at risk included the brainstem, spinal cord,
bilateral parotid and submandibular salivary glands (in
which level IB was not a target), contralateral glottic lar-
ynx (in cases in which the ipsilateral larynx or hypophar-
ynx were targets), oral cavity, and lips. Spinal cord
contours were expanded by 3 mm to create a planning
organ at risk volume.
Chemotherapy was administered concurrent with RT in
patients with ECE at neck dissection or for advanced
nodal disease in patients receiving definitive RT.
In situ hybridization and immunohistochemical staining
Immunohistochemical (IHC) stains and in situ hybrid-
ization (ISH) studies were performed on 4-mm sections
from paraffin-embedded tissue blocks containing a repre-
sentative sample of untreated tumor for patients with tis-
sue blocks available in the Department of Pathology at
our institution. No ISH or IHC analysis was performed in
the definitive RT group, as tissue blocks for the majority
of these patients were not accessible from the outside
institution where the original diagnostic procedure had
been performed.
IHC staining for p16INK4a was performed per protocol
supplied by the manufacturer’s kit (CINtec Histology Kit;
MTM Laboratories, Heidelberg, Germany) and visualized
using the ultraView polymer detection system (Ventana
Medical Systems, Tucson, AZ) on a Ventana Benchmark
Ultra Autostainer. Tumors with >75% staining in both
the nucleus and cytoplasm were considered positive. ISH
for high-risk HPV was performed using the INFORM
HPV ISH assay (Ventana Medical Systems), which con-
sists of a cocktail directed against a subset of high-risk
HPV genotypes (HPV 16, 18, 33, 35, 39, 45, 51, 52, 56,
and 66). ISH for Epstein–Barr virus (EBV)-encoded RNA
(Ventana Medical Systems) was performed in accord with
the manufacturer’s protocol. Positive reactions for both
ISH assays were detected using the ISH I View Blue Plus
Detection Kit (Ventana Medical Systems) in accord with
the manufacturer’s instructions. For HPV scoring, tumors
were classified as positive if any dot-like nuclear signal
was present in tumor cell nuclei and negative when no
nuclear signal was present. For EBV-encoded RNA scor-
ing, tumors were considered positive when tumor cell
nuclei demonstrated diffuse staining.
Statistical analysis
Baseline characteristics between groups were compared
using the independent samples t test for continuous varia-
bles, the Mann–Whitney test for ordinal variables, and
either the Fisher’s exact test or chi-square test for cate-
gorical variables. Clinical endpoints for this study were
overall survival (OS), progression-free survival (PFS),
locoregional relapse-free survival (LRFS), freedom-from-
locoregional failure (FFLRF), and freedom-from-distant
failure (FFDF), and were all calculated from the start date
of RT using Kaplan–Meier methods. The log-rank test
was used to evaluate statistical differences in survival out-
comes between groups. A significance level of 0.05 was
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used for all comparisons. All analyses were performed
using MedCalc (v12.4.0.0, MedCalc Software, Maria-
kerke, Belgium).
RESULTS
Forty-one patients diagnosed with HNCUP and treated
with either neck dissection1RT or definitive RT were
identified and included in the present analysis. Twenty-
two patients were treated with neck dissection1RT, and
19 were treated with definitive RT. Two patients under-
went definitive RT followed by planned neck dissection
within 3 months and are included in the neck dissec-
tion1RT group. Of a total of 41 patients, 37 were men
(90%). Median age at diagnosis was 53 years (range, 38–
72 years) for both groups. Patient characteristics are listed
in Table 1.
In the neck dissection1RT group, the initial diagnosis
of SCC was made by excisional biopsy in 4 patients
(18%) and fine-needle aspiration in 18 patients (82%)
(Table 2). In the RT group, 12 of 19 patients (63%)
underwent excisional biopsy for diagnosis before RT; of
these, ECE was present in 5, absent in 4, and not speci-
fied in 3. Either ECE or gross residual tumor after exci-
sional biopsy was present in 8 of these 12 patients (67%).
In both the neck dissection1RT and definitive RT
groups, the most common site of nodal involvement at
the time of presentation was level II (90%), followed by
level III (41%). Approximately 50% of patients with level
II and 20% with level III nodes presented with isolated
involvement at these levels; the remainder of patients had
involvement of additional levels. No patient presented
with isolated involvement at other neck levels. In the
neck dissection1RT group, 12 patients had pathological
evidence of ECE, whereas 5 patients had no ECE; no
information regarding ECE was available for the remain-
ing 5 patients. The distribution of nodal involvement at
presentation by clinical nodal classification and nodal
characteristics was similar between groups and is detailed
in Tables 3 and 4. Although there was a higher preva-
lence of N3 disease in the neck dissection1RT group
(27%) than the definitive RT group (16%), this difference
was not statistically significant (p5 .62).
Twenty-eight patients (68.3%) received IMRT, 13 in
the neck dissection1RT group and 15 in the definitive
RT group (p5 .31). Eleven patients (50%) in the neck
dissection1RT group, and 14 patients (74%) in the
definitive RT group received concurrent chemotherapy
(p5 .20), consisting of cisplatin in 12 patients, carbopla-
tin in 5 patients, 5-fluorouracil-carboplatin in 1 patient,
and carboplatin-paclitaxel in 7 patients.
Four patients (18%) required feeding tubes during the
treatment in the neck dissection1RT group compared
with 1 patient (5%) in the RT group (p5 .43). No patient
required a long-term (>6 months) feeding tube.
Follow-up for living patients was shorter in the defini-
tive RT group (median, 39 months; range, 11–98 months)
than the neck dissection1RT group (median, 73 months;
range, 18–126 months; p5 .01) because of the more prev-
alent use of neck dissection1RT in the earlier period of
this study (median year of diagnosis for definitive RT
group vs neck dissection1RT groups: 2006 vs 2003,
respectively). Overall, 4 patients died of disease: 3 in the
neck dissection1RT group, and 1 in the definitive RT
group. OS at 2 and 4 years for the neck dissection1RT
group was 90.7% and 85.3%, compared to 93.3% and
85.6% in the definitive RT group, respectively (p5 .64).
TABLE 1. Patient characteristics.
Neck dissection1 RT Definitive RT
Age, y, median (range) 53 (37–72) 53 (38–76)
Year of diagnosis,
median (range)
2003 (1994–2008) 2006 (1994–2008)
Follow-up, mo,
median (range)
73 (18–126) 39 (11–98)
No. of patients (%) No. of patients (%)
Sex
Male 20 (90) 17 (90)
Female 2 (10) 2 (10)
Smoking history,
>10 pack-years
Past 5 (23) 5 (26)
Current 8 (36) 5 (26)
Smoking1 alcohol 6 (27) 5 (26)
Tonsillectomy
Childhood 4 (18) 4 (21)
Current 4 (18) 7 (77)
Abbreviation: RT, radiation therapy.
FIGURE 1. Progression-free survival (A) and locoregional relapse-
free survival (B) after neck dissection (ND) and radiation therapy
(RT) or definitive RT in head and neck squamous cell carcinoma
of unknown primary.
NECK DISSECTION PLUS RT VERSUS DEFINITIVE RT
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PFS and LRFS (Figure 1) were similar in the neck dissec-
tion1RT and the definitive RT groups (PFS at 4 years,
67.9% vs 70.1%; p5 .82; LRFS at 4 years, 76.1% vs
75.0%; p5 .99; respectively). FFLRF was also not differ-
ent between the neck dissection1RT and definitive RT
groups (90.9% vs 88.8%; p5 .84), with no locoregional
recurrences observed after 19 months. OS and PFS did
not differ between patients who did and did not undergo
PET/CT staging either in the overall cohort (p5 .21 for
OS; p5 .69 for PFS) or within each treatment group
(neck dissection1RT, p5 .55 for OS; p5 .83 for PFS;
definitive RT, p5 .21 for OS; p5 .35 for PFS).
Emergence of a primary mucosal tumor occurred in 2
patients (5%), 1 patient in each group, at 9 and 15 months
after completion of RT. Both occurred in the ipsilateral
tonsillar fossae, within the previously irradiated CTVs
that received 50.4 Gy and 60 Gy, respectively. Two
patients (11%) in the definitive RT group required sal-
vage neck dissection because of suspicious clinical or
radiologic findings after therapy, but only in 1 patient
was cancer found in the dissected specimen.
One patient in each group (5% overall) experienced
ipsilateral neck recurrence. The patient in the definitive
RT group presented with initial N3 disease in level II and
experienced an in-field nodal recurrence in the same level
19 months after completion of RT. He was successfully
salvaged by radical neck dissection. The patient in the
neck dissection1RT group was initially treated for N2b
disease in level II with definitive RT followed by planned
neck dissection, and experienced recurrence 16 months
after completion of RT in the subcutaneous fat of ipsilat-
eral level IB, outside of the CTV. He underwent success-
ful surgical excision and remains without evidence of
disease at last follow-up.
Distant metastases were observed in 11.2% in the RT
group and in 28.1% in the neck dissection1RT group
(FFDF 88.8% vs 71.9%, respectively, p5 .26). Metastatic
sites were lung (4 patients), liver (2 patients), and perito-
neal and base of skull metastases (1 patient each). Two
cases of second primary tumors were observed in the
neck dissection1RT group (1 case with lung and 1 with
hepatocellular carcinoma) and 1 case in the definitive RT
group (melanoma).
Presence of HPV and EBV gene expression was
assessed only for patients in the neck dissection1RT
group (Table 4), as adequate material was not available
for the definitive RT group. For 17 patients with assess-
able HPV status, 10 (59%) were HPV-positive, whereas 7
(41%) were HPV-negative. HPV-positive patients were
significantly more likely than HPV-negative patients to
have nonkeratinizing tumor histology (100% vs 43%;
p5 .019) and were younger (median age 52 vs 61 years;
p5 .08), but did not differ from HPV-negative patients in
year of diagnosis (p5 .38), smoking status (history of
[ge]10 pack-years in 50% vs 71%; p5 .62), nodal classi-
fication (p5 .50), cystic-type nodal presentation (78% vs
71%; p5 1.00), or tumor differentiation (poorly differen-
tiated in 100% vs 71%; p5 .18). Patients treated in the
2000s were numerically more likely to be HPV-positive
than those treated in the 1990s (8 of 12 patients vs 2 of 5
patients; p5 .59). HPV-positive patients had a trend
toward superior PFS (80.0% vs 38.1% at 4 years; hazard
ratio, 0.29; p5 .15) and OS (100% vs 53.6% at 4 years;
hazard ratio, 0.17; p5 .06) compared to HPV-negative
patients. EBV status was determined for 7 patients in the
neck dissection1RT group who were not HPV-positive.
One of the 7 patients was EBV-positive; notably, this
patient was of white ethnicity with nonkeratinizing,
poorly differentiated SCC.
DISCUSSION
Because of a lack of randomized trials, the management
of patients with HNCUP remains a challenge regarding
both the therapeutic options (surgery alone vs surgery
plus RT vs RT) and the RT volumes (ipsilateral neck vs
bilateral neck and the putative mucosal sites).1–3,5,12
Although neck dissection with postoperative RT is the
most common treatment approach, the results of this ret-
rospective study suggest that primary RT, mostly concur-
rent with chemotherapy with surgery reserved for salvage
of locoregional failure, may achieve similar therapeutic
results.3,5,13 The presenting characteristics of our patient
population are consistent with those in prior reports on
HNCUP, with typical features including unilateral neck
involvement and level II as the most frequent site of cer-
vical metastasis.6,14–16
Surgery alone is typically the preferred primary
approach in patients with early-stage neck disease without
radiographic evidence of ECE and no history of surgical
violation of the neck, with high rates of regional control
demonstrated after neck dissection alone in a number of
studies.1–3,17–19 For example, Christiansen et al20
observed significantly higher 5-year survival and neck
control rates (55.6% vs 18.2% and 90.9% vs 40.9%,
respectively) for patients treated with neck dissection and
adjuvant RT compared with biopsy plus RT. Wallace et
al21 similarly noted superior neck control and cause-
specific survival in patients with HNCUP undergoing
neck dissection in addition to RT. In contrast, Colletier et
al3 observed no regional recurrences after excisional
biopsy and definitive RT despite the presence of N2 dis-
ease or ECE in 41% and 25% of these patients, respec-
tively. Nguyen et al22 further demonstrated no survival or
regional control benefit with the use of neck dissection
rather than excisional biopsy before RT, despite the pres-
ence of N2 or N3 disease in 91% of their patients with
TABLE 2. Diagnostic and treatment modalities.
Neck dissection1 RT Definitive RT
No. of patients (%) No. of patients (%)
Imaging techniques
CT 19 (86) 18 (94)
MRI 1 (5) 2 (10)
PET/CT 12 (55) 15 (79)
Surgical modalities
Excisional biopsy 4 (18)* 12 (63)
Radical 5 (23) N/A
Modified radical 17 (77) N/A
Chemotherapy
Concurrent 11 (50) 14 (74)
Abbreviations: RT, radiation therapy; PET, positron emission tomography; N/A, not available.
*Before neck dissection.
DEMIROZ ET AL.
1592 HEAD & NECK—DOI 10.1002/HED NOVEMBER 2014
HNCUP cohort. Our results are in line with the latter
series demonstrating similar tumor control rates in the
surgery1RT compared with the definitive RT groups.
Control of the unknown primary mucosal site is another
important consideration in management of HNCUP. In 1
series of 277 patients with HNCUP, Grau et al15 demon-
strated that whereas neck control was similar between
patients treated with surgery alone, definitive RT alone,
or surgery with adjuvant RT, emergence of the mucosal
primary was significantly higher in patients treated with
surgery alone (54% vs 15% at 5 years). Similar results
have been consistently reported in a number of stud-
ies.3,5,6,16,23 A review of the literature, shown in Table 5,
demonstrates 5-year locoregional control and emergence
of mucosal primary tumor rates ranging from 29% to
100% and 2% to 54%, respectively. The reasons for these
wide ranges are likely related to the different manage-
ment strategies, as summarized above. In the present
study, all patients received extended field RT irrespective
of treatment group; accordingly, no difference in control
of the primary mucosal site was observed.
Emergence of a primary mucosal tumor in the hypo-
pharynx and larynx has been reported to occur less fre-
quently than in the nasopharynx and oropharynx, leading
some to suggest that these sites may be safely excluded
from the extended RT fields to reduce treatment toxicity
in selected patients with HNCUP.21,24 This consideration
is especially relevant to nonsmokers and patients with
HPV-positive nodal metastases, in whom the primary
tumor is highly likely to be oropharyngeal.25–27 HPV
expression has additionally been demonstrated in signifi-
cant proportion of white patients with nasopharyngeal car-
cinomas, implying that the ipsilateral nasopharynx should
remain included in the target volume in patients with
HPV-positive EBV-negative HNCUP.28,29 Patients with
EBV-expression in metastatic lymph nodes, on the other
hand, are highly likely to have occult nasopharyngeal pri-
mary tumors, and, in these patients, the hypopharynx, lar-
ynx, and oropharynx can be excluded.30–33 In our series,
EBV-RNA was detected in 1 patient with nonkeratinizing
poorly differentiated SCC, who notably was of white-
American ethnicity, consistent with the reported occur-
rence of EBV-positive nasopharyngeal carcinoma in non-
endemic populations.29
In our present study, 59% of patients for whom HPV
status could be determined were HPV-positive. Although
HPV status was strongly associated with nonkeratinizing
tumor histology, as in other studies, it was not associated
with year of diagnosis, cystic node presentation, tumor
differentiation, or smoking status, in contrast to previous
reports.25,27,34 HPV expression was also associated with a
nonsignificant trend toward improved PFS (p5 .15) and
OS (p5 .06), analogous to those with HPV-positive SCC
of known oropharyngeal origin.11,26,30,34,35
One important source of potential confounding in our
study is the lack of information on HPV status in the
definitive RT group. Because the definitive RT group was
treated in more recent years, over which time the inci-
dence of HPV-associated oropharyngeal cancer has
increased, it is possible that a greater proportion of less
favorable HPV-negative patients in the neck dissec-
tion1RT group could have masked any potential benefit
of adding neck dissection to RT.36 Additional limitations
of our study design include its retrospective design, which
precludes reliable estimation of functional outcomes for
comparison between patients who received definitive RT
and neck dissection1RT, and the relatively small study
cohort. As with any nonrandomized retrospective study,
the possibility of selection bias as a source of confound-
ing between treatment groups cannot be excluded, which
may mask potential differences in efficacy between neck
dissection1RT and definitive RT. This remains an
important consideration, even despite the fact that no sta-
tistical differences in baseline characteristics were
observed. Examples of such potential sources of imbal-
ance between arms include the fact that excisional biopsy
at diagnosis removed all gross nodal disease in 9 of 19
patients in the definitive RT arm (compared with use of
excisional biopsy in 4 of 22 patients of the neck
TABLE 4. Tumor characteristics.
Neck dissection1 RT,
no. of patients (%)
Definitive RT,
no. of patients (%)
Clinical nodal stage at presentation
N1 2 (9) 2 (10)
N2a 6 (27) 4 (21)
N2b 8 (36) 10 (53)
N2c 0 (0) 0 (0)
N3 6 (37) 3 (16)
Nodal levels involved at presentation
I 1 (5) 2 (11)
II 18 (82) 19 (100)
III 11 (50) 6 (32)
IV 4 (18) 2 (11)
V 1 (5) 1 (5)
Multiple 10 (45) 7 (37)
ECE
No 5 (23) N/A
Yes 12 (55) N/A
N/A 5 (23) N/A
HPV status
Positive 10 (32) N/A
Negative 7 (45) N/A
N/A 5 (23) N/A
Abbreviations: RT, radiation therapy; ECE, extracapsular extension; N/A, not available; HPV,
human papillomavirus.
TABLE 3. Distribution of involved nodes at presentation by clinical
nodal stage.
Distribution by neck level
I II III IV V
Neck dissection1 RT
N1 2
N2a 4 3
N2b 1 7 4 2 1
N3 5 4 2
Definitive RT
N1 2
N2a 4 1
N2b 1 10 3 2 1
N3 1 3 2
Abbreviation: RT, radiation therapy.
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dissection1RT arm), the use of concurrent chemotherapy
in 14 definitive RT patients compared to 11 patients who
underwent neck dissection1RT, and the presence of N3
disease in 3 patients who underwent definitive RT com-
pared to 6 patients who underwent neck dissection1RT.
It is similarly possible that selection of poorer prognosis
patients for more aggressive therapy may account for the
higher observed frequency of distant metastases in the
neck dissection1RT arm (28.1% vs 11.2%), although this
difference was not statistically significant (p5 .26) and no
such trends were observed for the endpoints of LRFS
(p5 .99), PFS (p5 .82), and OS (p5 .64). Nevertheless,
these potential sources of imbalance, as well as the rela-
tively small number of included patients and observed
events, may limit the statistical power of our study to
detect the difference in outcomes between treatment
modalities, warranting the inclusion of larger numbers of
patients in a randomized prospective study that can appro-
priately stratify for such prognostic factors and background
treatment. Given the high rates of survival and locore-
gional control in both groups of our study, however, it is
unlikely that a significantly larger study of similar retro-
spective design would demonstrate a difference in outcome
between treatment modalities that could not be at least in
part attributed to confounding or selection bias.
In recent years, combined-modality therapy for locally
advanced, known primary head and neck SCC has been
shown to yield outcomes superior to RT alone in both the
definitive and adjuvant settings.37–39 The role of concurrent
chemotherapy in SCC of unknown primary, however, has
not yet been conclusively established and could not be
assessed in the current series, in which most patients in both
arms received concurrent chemotherapy. Extrapolating from
the demonstrated benefits in studies of known primary can-
cers, the administration of concurrent chemotherapy with
definitive RT for locally advanced disease and with adju-
vant RT for patients with ECE at neck dissection is advised.
In summary, comprehensive extended field RT deliv-
ered either as definitive therapy or adjuvantly after neck
dissection produced high rates of mucosal and neck con-
trol in patients with HNCUP. Patients treated with the
combination of neck dissection and RT had similar out-
comes to those treated with definitive RT without neck
dissection. Our results suggest that definitive RT either
with or without concomitant chemotherapy is sufficient
for the up-front management of HNCUP, with neck dis-
section reserved for salvage of regional failure.
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